A REVIEW ON METHOD DEVELOPMENT AND VALIDATION OF FAVIPIRAVIR BULK AND THEIR TABLET DOSAGE FORM

A REVIEW ON METHOD DEVELOPMENT AND VALIDATION OF FAVIPIRAVIR BULK AND THEIR TABLET DOSAGE FORM
Author(s):
Loganathan A, NALLA KUMAR P, PONNILAVARASAN I, VIGNESH S, GOWTHAM D
Keywords:
RP-HPLC, UV, RP-UPLC, NMR\LC-MS,UPLC.
Abstract
Favipiravir is an antiviral drug that was initially developed for influenza by Toyama Chemical, which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called Favipiravir. In this article, we have tried to provide a complete, evidence-based review of this drug in the perspective of the present pandemic to give further details about its role in the management of COVID-19. Favipiravir is a very widely used pharmaceutical, consequently it has been detected in the water system. The aim of this review is to focus on update of determination of Favipiravir in bulk and in pharmaceutical preparations using chromatographic and spectrophotometric methods. Favipiravir are estimated by RP-HPLC, UV, HPLC, RP-HPLC,UPLC, methods. For subjective and quantitative estimation of Favipiravir these diagnostic techniques can be utilized. This review provides detailed information on separation conditions for Favipiravir in the presence of drug and in presence of its degradation products.
Article Details
Unique Paper ID: 158529 Publication Volume & Issue: Volume 9, Issue 9 Page(s): 615 - 620
Article Preview & Download

Share This Article

NCSST-2021

AICTE Sponsored National Conference on Smart Systems and Technologies

Last Date: 25th November 2021

LATEST INNOVATION’S AND FUTURE TRENDS IN MANAGEMENT

Last Date: 7th November 2021